BALA CYNWYD, Pa., Oct. 03, 2022 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following research. If you own stock and would like to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. You will not incur any costs or financial obligations.
LogicBio Therapeutics, Inc. (Nasdaq – LOGC)
Under the terms of the merger agreement, LogicBio will be acquired by Alexion, AstraZeneca Rare Disease (“Alexion”). LogicBio shareholders will receive $2.07 in cash for each share of the company they own. The investigation concerns whether LogicBio’s board of directors failed in its fiduciary duty to shareholders by failing to conduct a fair trial and whether Alexion is underpaying the company. For example, the transaction consideration is below the 52-week high of $4.54 for the company’s shares.
For more information, see https://www.brodskysmith.com/cases/logicbio-therapeutics-inc-nasdaq-logc/.
O2Micro International Limited (Nasdaq – OIIM)
Under the terms of the Agreement, O2Micro will be acquired by FNOF Precious Honor Limited (“FNOF”). Each ADS of the Company representing fifty shares of common stock will be exchanged for the right to receive $5.00 in cash per ADS with no interest. The investigation concerns whether O2Micro’s board of directors breached its fiduciary duties to shareholders by failing to conduct a fair trial and whether FNOF underpays the company.
For more information, see https://www.brodskysmith.com/cases/o2micro-international-limited-nasdaq-oiim/.
Coffee Holding Co., Inc. (Nasdaq – JVA)
Under the terms of the agreement, Coffee Holdings will merge with Delta Corp Holdings Limited (“Delta”). Delta shareholders are expected to collectively own approximately 95.21% of the outstanding common shares and immediately prior to the closing of the transaction, Coffee Holding shareholders are expected to collectively own…
